全文获取类型
收费全文 | 6406篇 |
免费 | 466篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 321篇 |
妇产科学 | 140篇 |
基础医学 | 1037篇 |
口腔科学 | 57篇 |
临床医学 | 659篇 |
内科学 | 1223篇 |
皮肤病学 | 65篇 |
神经病学 | 750篇 |
特种医学 | 178篇 |
外国民族医学 | 1篇 |
外科学 | 654篇 |
综合类 | 42篇 |
预防医学 | 644篇 |
眼科学 | 55篇 |
药学 | 496篇 |
中国医学 | 26篇 |
肿瘤学 | 484篇 |
出版年
2023年 | 34篇 |
2022年 | 62篇 |
2021年 | 171篇 |
2020年 | 103篇 |
2019年 | 159篇 |
2018年 | 180篇 |
2017年 | 130篇 |
2016年 | 148篇 |
2015年 | 180篇 |
2014年 | 200篇 |
2013年 | 315篇 |
2012年 | 429篇 |
2011年 | 510篇 |
2010年 | 262篇 |
2009年 | 254篇 |
2008年 | 424篇 |
2007年 | 439篇 |
2006年 | 404篇 |
2005年 | 399篇 |
2004年 | 398篇 |
2003年 | 358篇 |
2002年 | 347篇 |
2001年 | 46篇 |
2000年 | 48篇 |
1999年 | 58篇 |
1998年 | 70篇 |
1997年 | 67篇 |
1996年 | 64篇 |
1995年 | 50篇 |
1994年 | 43篇 |
1993年 | 43篇 |
1992年 | 40篇 |
1991年 | 32篇 |
1990年 | 39篇 |
1989年 | 34篇 |
1988年 | 25篇 |
1987年 | 38篇 |
1986年 | 28篇 |
1985年 | 37篇 |
1984年 | 36篇 |
1983年 | 28篇 |
1982年 | 24篇 |
1981年 | 22篇 |
1980年 | 24篇 |
1979年 | 13篇 |
1978年 | 16篇 |
1977年 | 10篇 |
1973年 | 7篇 |
1971年 | 6篇 |
1970年 | 6篇 |
排序方式: 共有6895条查询结果,搜索用时 83 毫秒
101.
Wendy A G Stams Monique L den Boer H Berna Beverloo Jules P P Meijerink Elisabeth R van Wering Gritta E Janka-Schaub Rob Pieters 《Clinical cancer research》2005,11(8):2974-2980
PURPOSE: t(12;21)(p13; q22), present in approximately 25% of pediatric precursor B-ALL, is highly sensitivity to L-asparaginase and the prognosis depends on the intensity of the treatment protocol. This study analyzes the relationship between the mRNA expression of the genes and fusion products involved in t(12;21), in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, and long-term clinical outcome in t(12;21)+ acute lymphoblastic leukemia (ALL) patients. EXPERIMENTAL DESIGN: Long-term clinical outcome in 45 t(12;21)+ ALL patients was related to mRNA expression of TEL, AML1, TEL-AML1, and AML1-TEL, determined by real-time quantitative PCR, and the in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. RESULTS: A significant approximately 3.5-fold lower TEL expression in t(12;21)+ compared with t(12;21)- ALL samples (P = 0.006) and normal controls (P = 0.004) was found. Expression of AML1 did not differ between t(12;21)+ and t(12;21)- ALL. However, AML1 expression in the leukemic cells was 2-fold higher compared with normal controls (P = 0.02). The TEL-AML1 fusion product was expressed in all t(12;21)+ cases, whereas the reciprocal fusion product AML1-TEL was expressed in only 76%. High expression levels of TEL-AML1 [hazard ratio (HR), 1.3; 95% confidence interval (95% CI), 1.10-1.57; P = 0.003], AML1-TEL (HR, 4.9; 95% CI, 1.99-12.40; P = 0.001) and AML1 (HR, 1.1; 95% CI, 1.03-1.22; P = 0.006) were associated with a poor long-term clinical outcome within t(12;21)+ ALL. Cellular drug resistance towards prednisolone, vincristine, and L-asparaginase could not explain this predictive value. Multivariate analysis including age and WBC showed that only high AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL. CONCLUSION: High AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL. 相似文献
102.
Michel Ducreux Marc Ychou Agnès Laplanche Erick Gamelin Philippe Lasser Fares Husseini Fran?ois Quenet Frédéric Viret Jacques-Henri Jacob Valérie Boige Dominique Elias Jean-Robert Delperro Monique Luboinski 《Journal of clinical oncology》2005,23(22):4881-4887
PURPOSE: Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs. Oxaliplatin combined with fluorouracil (FU) and leucovorin is effective in the treatment of colorectal cancer. In this context, a phase II study was conducted to evaluate concomitant administration of oxaliplatin by HAI and intravenous (IV) FU plus leucovorin according to the LV5FU2 protocol (leucovorin 200 mg/m(2), FU 400 mg/m(2) IV bolus, FU 600 mg/m(2) 22-hour continuous infusion on days 1 and 2 every 2 weeks). PATIENTS AND METHODS: Patients had metastatic colorectal cancer that was restricted to the liver and inoperable. The patients were not to have previously received oxaliplatin. After surgical insertion of a catheter in the hepatic artery, patients were treated with oxaliplatin 100 mg/m(2) HAI combined with FU + leucovorin IV according to the LV5FU2 protocol. Treatment was continued until disease progression or toxicity. Response was evaluated every 2 months. RESULTS: Twenty-eight patients were included, and 26 patients were treated. Two hundred courses of therapy were administered, and the median number of courses received was eight courses (range, zero to 20 courses). The most frequent toxicity consisted of neutropenia. The main toxicity related to HAI was pain. The intent-to-treat objective response rate was 64% (95% CI, 44% to 81%; 18 of 28 patients). With a median follow-up of 23 months, the median overall and disease-free survival times were 27 and 27 months, respectively. CONCLUSION: The combination of oxaliplatin HAI and FU + leucovorin according to the LV5FU2 protocol is feasible and effective in patients presenting with isolated hepatic metastases of colorectal cancer. 相似文献
103.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
104.
Véronique Lenoir Marianne Beau Yon de Jonage-Canonico Marie-Hélène Perrin Antoine Martin Robert Scholler Bernard Kerdelhué 《Breast cancer research : BCR》2005,7(4):R470
Introduction
It has been well documented that the pineal hormone, melatonin, which plays a major role in the control of reproduction in mammals, also plays a role in the incidence and growth of breast and mammary cancer. The curative effect of melatonin on the growth of dimethylbenz [a]anthracene-induced (DMBA-induced) mammary adenocarcinoma (ADK) has been previously well documented in the female Sprague-Dawley rat. However, the preventive effect of melatonin in limiting the frequency of cancer initiation has not been well documented. 相似文献105.
106.
The power of positive deviance 总被引:1,自引:0,他引:1
David R Marsh Dirk G Schroeder Kirk A Dearden Jerry Sternin Monique Sternin 《British medical journal》2004,329(7475):1177-1179
107.
108.
109.